When Albert Bourla took over as CEO of Pfizer in January 2019, he said he wanted the pharmaceutical giant to be a more focused, innovative, science-based company. Bourla now finds himself at the forefront of developing and testing a COVID-19 vaccine in partnership with Germany’s BioNTech. Underway with a late-stage clinical trial for its vaccine, if successful, Pfizer said they could supply up to 100 million doses of the vaccine by the end of 2020. Bourla will discuss the timeline for a safe and effective vaccine and the state of the health industry during these uncertain times. Join Washington Post senior writer Frances Stead Sellers on Thursday, Aug. 6 at 2:00 p.m. ET.
Washington Post Live is the newsroom’s live journalism platform, featuring interviews with top-level government officials, business leaders, cultural influencers and emerging voices on the most pressing issues driving the news cycle nationally and across the globe. From one-on-one, newsmaker interviews to in-depth multi-segment programs, Washington Post Live brings The Post’s newsroom to life on stage. Subscribe to The Washington Post on YouTube: https://wapo.st/2QOdcqK